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Abstract
The expression of secreted protein acidic and rich in cysteine 
(SPARC) has been associated with the malignant progression 
of different types of human cancer. SPARC was associated with 
tumor cell capacity to migrate and invade, although its precise 
role in tumor progression is still elusive. In the present study, 
we show that SPARC produced by melanoma cells modulates 
the antitumor activity of polymorphonuclear leukocytes 
(PMN). Administration to nude mice of human melanoma 
cells in which SPARC expression was transiently or stably 
knocked down by antisense RNA (SPARC-sup cells) promoted 
PMN recruitment and obliterated tumor growth even when 
SPARC-sup cells accounted for only 10% of injected malignant 
cells. In addition, SPARC-sup cells stimulated the in vitro 
migration and triggered the antimelanoma cytotoxic capacity 
of human PMN, an effect that was reverted in the presence of 
SPARC purified from melanoma cells or by reexpressing 
SPARC in SPARC-sup cells. Leukotrienes, interleukin 8, and 
growth-related oncogene, in combination with Fas ligand and 
interleukin 1, mediated SPARC effects. These data indicate 
that SPARC plays an essential role in tumor evasion from 
immune surveillance through the inhibition of the antitumor 
PMN activity. (Cancer Res 2005; 65(12): 5123-32)
Introduction
Secreted protein acidic and rich in cysteine (SPARC) is a secreted 
glycoprotein that has been implicated in tumor-host interactions 
by virtue of its ability to modulate cellular interaction with the 
extracellular matrix (1). SPARC interacts with several extracellular 
matrix components, binds and modulates the activity of specific 
growth factors, and regulates matrix metalloproteinase expression 
and activity (2). Moreover, SPARC expression is associated with 
tissue remodeling processes, like wound healing and angiogenesis, 
both of which include physiologic steps of invasive phenotypes (3). 
Several reports associated SPARC expression with the invasive and 
metastatic capacity of different human cancers although its precise 
role in tumor progression is still controversial (4-7). Suppression of 
SPARC expression in human melanoma cells abrogated their 
tumorigenic capacity (4). However, breast carcinoma and glioma 
cells engineered to express SPARC showed reduced tumor cell 
proliferation probably due to the capacity of SPARC to inhibit cell 
cycle (7) and SPARC expression in ovarian carcinoma cells 
impaired their tumorigenic potential (8). Interestingly, SPARC 
production by tumor stromal cells has been also associated with 
the neoplastic progression of tumors in which SPARC is hardly 
detected in the malignant cells themselves (9, 10).
The role of inflammatory cells in tumor progression is highly 
controversial. Inflammatory cells can promote tumor progression 
by degrading the extracellular matrix, activating tumor-associated 
fibroblasts, and enhancing angiogenesis (11). Conversely, inflam­
matory cells can be activated to eliminate tumor cells (12) or might 
release cytokines that activate professional antigen presenting cells 
that recruit specific immune effector cells with the capacity to 
complete tumor rejection (13). Only very recently, the role of 
polymorphonuclear leukocytes (PMN) in the immune surveillance 
against tumors has emerged. PMNs are the first line of defense 
against infection. They release soluble chemotactic factors and 
proteases that alter the microenvironment inducing extracellular 
matrix remodeling and recruitment of nonspecific and specific 
immune effector cells (11). Recent reports highlighted the 
participation of PMNs as direct effector cells in the immune 
surveillance against cancer (14).
In a previous work, we have shown that suppression of SPARC 
expression in human melanoma cells prevented tumor growth in 
nude mice in coincidence with the massive recruitment of PMN to 
the site of tumor cell injection (4). Here we show for the first time 
that stable and transient knockdown of SPARC expression in 
different human melanoma cell lines promoted the in vivo PMN 
recruitment and rejection of tumor cells in nude mice and 
triggered the in vitro migration and antitumor cytotoxic capacity of 
human PMN (hPMN). PMN activity was reverted in the presence of 
native SPARC and by reexpressing SPARC. We have identified 
chemotactic factors and molecules involved in apoptotic pathways 
that mediate SPARC effect both in vitro and in vivo. Overall, these 
results suggest that SPARC produced by malignant cells has an 
important role in the escape of tumor cells from antitumor 
immune surveillance by blocking PMN antitumor activity.
Materials and Methods
Cell lines, reagents, and antibodies. IIB-MEL-LES and A375N 
melanoma cell lines were grown in melanoma medium and IIB-MEL-J 
human melanoma cells were grown in melanoma medium containing 5 pg/ 
L epidermal growth factor and 500 pg/L transferrin, supplemented with 
10% fetal bovine serum (FBS) and antibiotics (4). Cultures were maintained 
at 37°C in a 5% C02 humidified incubator. L-1D and L-1E are stable cell 
clones selected in G418 (Invitrogen, Grand Island, NY) after transfection of 
IIB-MEL-LES cells with Rc/CMV vector (Invitrogen, San Diego, CA) 
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carrying SPARC full-length cDNA cloned in antisense orientation (4). 
Clones were thawed from original stocks, selected in G418, and routinely 
checked for SPARC production. L-CMV and L-p-gal cells were generated by 
stable transfection of IIB-MEL-LES cells with Rc/CMV vector alone or 
carrying the bacterial ^.-galactosidase gene, respectively.
Unless specified, the cell culture reagents were from Invitrogen (Grand 
Island, NY), and the chemicals were from Sigma (St. Louis, MO). MK-886 
was purchased from Calbiochem (San Diego, CA). The leukotriene B4/C4/ 
D4/E4 enzyme immunoassay system was from Amersham Pharmacia 
Biotech (Buckinghamshire, United Kingdom). Anti-Fas (B-G27) and anti- 
Fas ligand (NOK-1) monoclonal antibodies (mAb) and horseradish 
peroxidase-conjugated secondary antibody were from RDI (Flanders, NJ). 
Anti-interleukin (IL)-8, anti-growth-related oncogene (GRO)-a and anti- 
panGRO monoclonal antibodies, anti-IL-8 and anti-GRO-a polyclonal 
antibodies, and human recombinant IL-8 and GRO-a were from R&D 
Systems, Inc. (Minneapolis, MN). Anti-CD31 and anti-CD54 monoclonal 
antibodies were from the 6th International Workshop on human leukocyte 
differentiation antigens (HLDA6); anti-CD18 monoclonal antibody was from 
the HLDA3. Isotypic control mAbs and phycoerythrin-conjugated secondary 
antibodies were from DAKO A/S (Glostrup, Denmark).
Human SPARC was purified from A375N serum-free cell-conditioned 
medium (SF-CCM) conditioned for 24 hour's, clarified by centrifugation, 
supplemented with 1 mmol/L phenylmethylsulfonyl fluoride and 1 mmol/L 
ED TA, concentrated to 50 mL in an Arnicon ultrafiltration cell with YM10 
membrane, MW cutoff 10,000 (Millipore Corp., Billerica, MA), and dialyzed 
against 20 mmol/L Tris-HCl (pH 7.8). Samples were loaded on a HiTrap Q 
column (GE Healthcare, Piscataway, NJ) and eluted in a continuous salt 
gradient (100-800 mmol/L NaCl). After SPARC identification by Western 
blot, selected fractions were run in SDS-PAGE and those with purity higher 
than 90% were pooled, dialyzed against Tris 20 mmol/L, 150 mmol/L NaCl, 
pH 7.8, and run in a Superdex 200 column. The eluted fractions, showing 
98% purity, were dialyzed against PBS, concentrated with a Centricon 10 
(Millipore Corp., Billerica MA), sterilized by passing through a 0.22 mm pore 
filter, snap-frozen in liquid N2, and stored at — 80° C. Protein samples 
showed circular dichroism spectra similar to those reported for SPARC 
obtained from murine Engelbreth-Holm-Swarm tumors and were able to 
inhibit bovine aorta endothelial cell proliferation in vitro (15).5
5 F. Prada et al., manuscript in preparation.
Adenoviral constructs. A 1.7 kb Sall fragment containing the coding 
sequence of human SPARC and a 527 bp Sall fragment containing the 
bacterial fLgalactosidase gene were cloned in pADPSY-LTRSVpolyA vector 
to generate adenoviral vectors carrying SPARC cDNA in sense (AdSPARC) 
and antisense (AdSP-AS) orientations or Adp.gal, respectively. The 537 bp 
cDNA of IL-1 receptor antagonist was obtained by reverse transcription- 
PCR from lipopolysaccharide-stimulated rat spleen, cloned in pSP72 
plasmid and subcloned in the same vector. Adenoviral particles were 
produced as described (16). The concentration of recombinant vector was 
expressed as 50% tissue culture infectious doses (TCID50) per milliliter (17).
In vivo assays. Eight- to ten-week-old athymic N:NIH(S)-nu mice 
received s.c. injections of 5 x 106 melanoma cells in the left flank, in a total 
volume of 100 pL. Perpendicular diameters were used to determine tumor 
volume, as d± x d2 / 2, where d± is the smaller diameter and d2 is the larger 
one. Mice harboring tumors greater than 2 cm3 were considered not 
survivors and euthanized following institutional guidelines. Surviving 
mice were followed for 6 months.
For histologic analysis, the sites of injection were removed, paraffin 
embedded, cut, and stained with H&E. Immunohistochemical detection of 
PMN and macrophages was done on paraffin-embedded tissue with anti- 
Ly-6G antibody (RB6-8C5, BD PharMingen, San Diego, CA) and anti-F4/80 
antibody (A3-1, Serotec, Oxford, United Kingdom), respectively. Samples 
were stained with Vectastain ABC kit (Vector Lab., Burlingame, CA) and 
counterstained with hematoxylin.
For functional blocking assays, melanoma cells were preincubated for 30 
minutes with 2 pg antibody or 500 pmol MK886 in a final volume of 50 pL 
and injected in the left flank of nude mice. At the indicated times, the 
injection areas were removed, paraffin embedded, cut, and stained with 
H&E. PMNs were blindly evaluated by one of us (AI.B., an anatomopathol- 
ogist) using a light microscope under air and oil immersion at x630 
magnification, and confirmed in some cases by immunohistochemical 
detection in subsequent slides of the same area. Only clearly viable PMNs 
were quantified.
In vitro assays with human leukocytes. PMN, lymphocytes, and 
monocytes were isolated as described (18). Briefly, leukocytes obtained from 
venous blood of healthy human volunteers were resuspended in Tyrode’s 
solution containing 10% autologous platelet-poor plasma supplemented 
Percoll (Pharmacia Fine Chemicals, Dorval, PQ). Six different Percoll 
cushions were layered in a 15 mL conical tube followed by centrifugation at 
400 x g (25 minutes at 22° C). Harvested bands were washed twice with 
Tyroyd’s solution. PMN, monocytes, and lymphocytes were recovered with 
>90% purity and >95% viability as assessed by trypan blue exclusion. PMNs 
were identified by nuclear morphology following crystal violet staining; 
monocytes were identified by anti-CD14 flow cytometry; and lymphocytes 
were identified by anti-CD3 flow cytometry.
For migration assays, 1.25 x 105 PMNs or 2.5 x 105 monocytes or 
lymphocytes were seeded on 3 pm pore size Transwells inserts (Corning 
Costar, Cambridge, MA) and allowed to migrate for 45 minutes toward SF- 
CCM supplemented with 5 mg/mL human serum albumin (UNC 
hemoderivados, Córdoba, A'gentina). PMN migration in the presence of 
10 nmol/L formyl-Met-Leu-Phe was used as a positive control. Migrated 
cells were counted with a Cytoron Absolute flow cytometer (Ortho 
Diagnostic Systems, Raritan, NJ). For neutralization assays, 10 pg/mL each 
of anti-IL-8, anti-GRO, and anti-Fas ligand (FasL) antibodies were added to 
SF-CCM 30 minutes before the chemotaxis assay. For blocking leukotriene 
production, cells were preincubated overnight in melanoma media 
supplemented with 1 pmol/L MK886 followed by the preparation of SF- 
CCM containing 1 pmol/L MK886. For PMN migration assays toward 
melanoma cells, malignant cells were grown in 24-well plates and the 
culture supernatant was replaced with SF-CCM 1 hour before the assay. 
Isolated PMNs were seeded on 3 pm pore size transwells and allowed to 
migrate toward melanoma cells for 90 minutes. The number of migrated 
PMN was estimated by myeloperoxidase activity.
For adhesion analysis, hPMNs were incubated in 200 pCi 51Cr-containing 
PBS for 30 minutes. After washing, 51Cr-labeled hPMNs were incubated with 
melanoma cells in serum-free medium supplemented with 5 mg/mL human 
serum albumin. After 45 minutes, nonadherent PMNs were removed by 
washing with PBS supplemented with Ca2+ and Mg2+. The fraction of 
adherent PMN was obtained by using the following formula: 100 x aC / tC, 
where aC and tC are the 51 Cr counts corresponding to adherent and total 
PMN, respectively. For blocking adhesion, PMNs and melanoma cells were 
separately preincubated, each with 20 pg/mL antibody for 30 minutes, 
followed by incubation with the same amount of antibody during the 
adhesion assay. Expression of CD 18 at the cell surface of hPMN and of CD31 
and CD54 in both hPMNs and melanoma cells were confirmed by flow 
cytometry.
PMN azurofilic granule exocytosis was evaluated by myeloperoxidase 
release. Freshly isolated hPMN, preincubated for 5 minutes with 500 ng/mL 
cytochalasin B, were coincubated with melanoma CCM for 30 minutes 
and myeloperoxidase activity in the supernatant was quantified as 
described (19).
For cytotoxic assays, trypsinized melanoma cells were labeled with 
200 pCi 51Cr. hPMN samples were cocultured with labeled melanoma cells 
for 40 hours in 5% FBS-supplemented medium. At the end of the 
incubation period, the supernatant was harvested and cells were lysed with 
0.3 N NaOH. Specific lysis, expressed as percentage, was estimated from the 
radioactivity present in the different fractions with the following formula: 
100 x (tCs x sCi / tCi — sCs) / (tCs — sCs), where sCi and sCs are the 51Cr 
counts of supernatants that correspond to treatment i and spontaneous 
51Cr release control, respectively, and tCi and tCs are the total counts 
(supernatant plus cell lysate) for treatment i and spontaneous release 
control, respectively.
For PMN apoptosis determination, 5 x 105 hPMNs were incubated for 
16 hours in 100 pL of 5% FBS-supplemented melanoma medium alone 
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(basal treatment) or containing 500 nmol/L human SPARC. In parallel 
experiments, 5 x 105 hPMNs were coincubated with 2 x 10 ’ melanoma cells 
in 100 pL of 5% FBS-supplemented melanoma medium for 16 hours. PMN 
apoptosis was then evaluated by three different methods: (a) quantification 
of metabolically active apoptotic PMNs by flow cytometry after annexin V 
plus propidium iodide staining (annexin V:FITC apoptosis detection kit I, 
BD PharMingen); (b) flow cytometry of propidium iodide-stained ethanol- 
fixed cells (20); and (c) counting of metabolically active apoptotic PMNs in 
hemocytometer by inspection of their nuclear morphology after acrydine 
orange plus ethidium bromide staining (20).
ELISA assays and fluorescence-activated cell sorting analysis. IL- 
8 and GRO-a levels in SF-CCM were determined by ELISA following the 
instructions of the manufacturer (R&D Systems). For fluorescence-activated 
cell sorting analysis (FACS), subconfluent melanoma cells were detached 
with 1 mmol/L EDTA-supplemented PBS and labeled with anti-Fas, anti- 
FasL mAbs, and isotypic control mAbs, followed by phycoerythrin- 
conjugated secondary antibody in 0.01% NaN3-supplemented PBS. FACS 
analysis was done in a FACStar Plus flow cytometer (Becton Dickinson, 
Mountain View, CA).
Statistical analysis. Significance levels for orthogonal comparisons were 
estimated by one-way ANOVA. Analysis of data from several independent 
experiments was carried out with a mixed effects ANOVA taking the 
different experiments as random effects. Significance of multiple compar­
isons was estimated by Newman-Keuls test.
Results
Knockdown of SPARC expression in human melanoma cells 
enhances polymorphonuclear leukocyte recruitment in vivo 
and promotes rejection of human melanoma cells: kinetic 
study. First, we did a kinetic study of the evolvement of the host 
response following the injection of a cell clone (L-1D) that 
produced on average 20% or less SPARC than control L-CMV cells 
(Fig. L4). Eight hours after injection, we observed a similar 
inflammatory response in both L-1D and L-CMV injection sites, 
which was probably the result of host response to the xenogeneic 
transplant (data not shown). However, 24 hours was enough to 
observe clear histologic differences between samples. Indeed, mice 
injected with L-CMV cells showed tumor nodules with a 
conspicuous PMN infiltrate (Fig. IB, inset and data not shown). 
These tumors continued growing for over 12 days showing an 
increased extracellular matrix layer and only a scant PMN infiltrate 
(Fig. 1C and I) and data not shown). Conversely, injection of L-1D 
cells at 24 to 72 hours resulted in an increased inflammatory 
infiltrate compared with L-CMV cells (Fig. 3/1). This inflammatory 
infiltrate was composed mainly of PMNs that invaded the entire 
area of tumor cell injection with no evidence of viable tumor cells 
after 72 hours (Fig. IE and F). Starting from day 5 up to day 12, 
macrophages were seen to invade the site of injection (Fig. 1G-I, 
insets). At day 7 fibroblasts were also present (Fig. IFF). The area 
was completely cleared at day 12 when fibrotic tissue replaced the 
area of tumor injection (Fig. 11, inset).
To confirm that PMN recruitment is under the control of SPARC, 
we transiently blocked SPARC expression in a second human 
melanoma cell line, A375N. This cell line, which produced 5-fold 
the amount of SPARC produced by L-CMV cells, showed up to 90% 
reduction in secreted SPARC compared with Adpgal-transduced 
cells after transduction with AdSP-AS (Fig. 1J and K). Reduction in 
SPARC levels was steady for 3 days.5 A375N cells transduced ex vivo 
by AdSP-AS induced a strong PMN infiltrate at 72 hours compared 
with control cells transduced with Ad|'gal, with only few viable 
tumor cells and both viable and damaged PMN sparse in all the 
tumor areas (Fig. 1L-O). Moreover, AdSP-AS-transduced A375N 
cells showed reduced in vivo growth compared with control cells 
(Fig. IP). Similar results were obtained with another human 
melanoma cell line, IIB-MEL-J (data not shown). The whole data 
indicates that knockdown of SPARC expression in melanoma cells 
promotes a persistent PMN infiltrate associated with tumor 
rejection.
SPARC knockdown in melanoma cells promotes an in­
creased migration of human polymorphonuclear leukocytes 
in vitro. Next, we sought to establish whether knockdown of 
SPARC expression was directly affecting PMN migration in vitro. 
In addition to L-1D, we have also used the L-1E cell clone which 
expressed on average 40% of SPARC levels observed in L-CMV 
cells (Fig. L4). L-1D and L-1E cells (collectively referred to as SP-AS 
cells) were conditioned in serum-free medium for 1 hour as a 
chemotactic stimulus for PMN. Such a short conditioning period 
was sufficient to stimulate 2- to 3-fold the transmigration of mouse 
PMN (mPMN) compared with L-CMV cells (Fig. 2A). Similar results 
were obtained when SF-CCM conditioned for 16 hours was used 
as a chemotactic source (data not shown).
To further confirm SPARC effects, we used hPMN. In 59% of the 
samples (13 of 22), SF-CCM obtained from SP-AS cells induced on 
average a 2-fold increase in migration of hPMNs compared with L- 
CMV cells (Fig. 2B). hPMNs obtained from the other nine donors 
were equally attracted by both cell types (not shown). The 
chemotactic capacity of the CCM was specific for PMN because 
L-CMV and SP-AS CCM had no effect on human lymphocyte and 
monocyte transmigration capacity (Fig. 2C and D). Thus, the effect 
that SPARC knockdown showed on transmigration assays in vitro 
supported the likelihood that SPARC produced by the malignant 
cells modulated the in vivo PMN recruitment.
Specific chemotactic factors mediate SPARC effect in vivo 
and in vitro. We next attempted to identify the chemotactic 
factors that might be responsible for stimulating PMN recruitment 
in vivo and transmigration in vitro following knockdown of SPARC 
expression. IL-8 and GRO-a are likely candidates because they are 
produced by human melanoma and tumor stroma cells acting both 
as autocrine growth factors for melanoma cells and chemo­
attractants of PMN (21, 22). SP-AS cells produced higher levels of 
IL-8 than L-CMV cells (1,060 ± 120 pg/106 cells in L-1E, 1,750 ± 4.37 
pg/106 cells in L-1D, and 345 ± 10.8 pg/106 cells in L-CMV cells, 
mean ± SE from four experiments; P < 0.01, when L-1E and L-1D 
were compared versus L-CMV). In addition, GRO levels were 
undetectable in L-CMV cells, whereas L-1E produced as much as 
120 ± 19 pg/106 cells and L-1D cells produced 60+7 pg/106 cells. 
Despite this increased production, incubation of L-1D cells with 
neutralizing antibodies against IL-8 and GRO did not block L-1D- 
mediated mPMN recruitment in vivo and inhibited only by 22% 
hPMN migration in vitro (Fig 3A and B). These antibodies were 
physiologically active because they completely blocked the in vitro 
hPMN migration induced by L-CMV cells (Fig. 3B) and did not 
affect hPMN migration induced by formyl-Met-Leu-Phe (data not 
shown).
Leukotrienes are also potent chemotactic factors for PMN and 
are produced by human melanoma cells (23). Efforts to quantify 
the amount of leukotrienes produced by melanoma cells were 
unsuccessful because the amount was below the sensitivity of 
the assay (see Materials and Methods for details). To test 
leukotriene involvement, we treated melanoma cells with MK886, 
a specific inhibitor of 5-Iipoxygenase activating protein, which is 
an essential protein in leukotriene production (24). MK886 
treatment reduced by almost 40% the capacity of L-1D cells to
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Figure 1. Kinetic analysis of the host inflammatory response following injection of nude mice with melanoma cells in which SPARC expression was knocked 
down. A, immunoblot of SPARC in the cell-conditioned media of L-CMV, L-1E, and L-1D cells in 1 pg of total protein. Bto I, microphotographs corresponding to the area 
of injection of control L-CMV cells at 24 hours (B), 72 hours (C), and 5 days postinjection (D); L-1D cells 24 hours (E), 72 hours (F), 5 days (G), 7 days (H). and 
12 days after cell injection (/). E, inset, anti-PMN (Ly-6G antigen) immunostaining; G to I, insets, antimacrophage (F4/80 antigen) immunostainings. J and K, 
immunoblots of SPARC in 1 pg total protein from cell-conditioned media of melanoma cells transduced with the different adenoviral vectors. L to O, A375N human 
melanoma cells were transduced ex vivo with 5 \ 10s TCID50/mL particles of Adpgal and AdSP-AS adenoviral vectors 24 hours before s.c. injection in nude mice. 
Microphotographs correspond to the injection sites that were removed for histologic analysis at 24 hours for Adpgal (L) and AdSP-AS-transduced (/Vf) cells, and 
at 72 hours postinjection for Adpgal (N) and AdSP-AS-transduced (O) cells. Fi, fibroblast; M, macrophage; P, PMN; T, melanoma cell; V, blood vessel. Bar, 
10 pm. P, in vivo growth of A375N human melanoma cells. A375N cells were transduced ex vivo with 5 x 10sTCID50/mL particles of Adpgal and AdSP-AS adenoviral 
vectors. After 24 hours, untransduced (mock control) and adenovirus-transduced cells were injected s.c. in nude mice. Points, average tumor volume of eight 
mice; bars, SE. Representative of two experiments. *, P < 0.01.
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recruit PMN to the site of injection in vivo compared with 
vehicle-treated L-1D cells at 24 hours (Fig. 3.4 ). MK886 was also 
effective as a single agent at 72 hours, and its combination with 
anti-IL-8 and anti-GRO antibodies completely abrogated PMN 
recruitment induced by L-iD cells (Fig. 3/1). In in vitro studies, 
incubation of L-ID cells with either of the reagents separately 
did not significantly affect hPMN transmigration capacity (Fig. 
35). However, combinatorial treatment with MK886, anti-IL-8, 
and anti-GRO antibodies inhibited by almost 70% L-ID capacity 
to induce transmigration of hPMNs in three of five samples 
(Fig. 35) and was partially effective with PMNs from the other 
two donors (data not shown). From the whole data, it can be 
concluded that mPMN recruitment in vivo and hPMN migration 
in vitro that occurs as a result of knockdown of SPARC 
expression are mediated, at least in part, by leukotrienes, IL-8, 
and GRO.
Role of Fas ligand and interleukin 1 as mediators of SPARC 
effects. The role of FasL in immune surveillance is highly 
controversial (25). Previous evidence showed that tumor cells 
expressing FasL are rejected by challenged mice through a PMN- 
mediated mechanism (25). Moreover, soluble FasL was shown to be 
chemotactic for human and murine PMNs (26). Flow cytometry 
analysis showed no changes in the expression levels of Fas 
following knockdown of SPARC expression. However, FasL was 
detected at the cell surface in the two SP-AS clones tested, but not 
in control L-CMV cells (Fig. 3C). Interestingly, injection of L-ID 
cells treated with anti-FasL neutralizing antibody had no effect on 
PMN recruitment at 24 hours (Fig. 3A, 24 hours). However, a 
dramatic reduction in PMN recruitment was observed 72 hours 
postinjection, suggesting a role of FasL in the persistence of the 
PMN infiltrate (Fig. 3A, 72 hours). IL-1 was shown to be a 
Figure 2. In vitro leukocyte migration induced by melanoma cells.
A, mPMN migration towards melanoma cells with their CCM. Migrated PMNs 
were quantified by their myeloperoxidase activity. Columns, average percentage 
of PMN migration from two independent experiments; bars, SE. *, P < 0.01.
B, hPMN migration induced by melanoma cell-conditioned media. Migrated 
PMNs were quantified by absolute flow cytometry. Columns, average 
percentage of PMN migration obtained from 13 selected donors; bars, SE.
*, P < 0.05; **, P < 0.0001. C and D, human monocyte (C) and lymphocyte (D) 
migration induced by melanoma cell-conditioned media. Migrated leukocytes 
were quantified by absolute flow cytometry. Columns, average percentage of 
migration; bars, SE. Representative of two experiments.
Human monocyte migration 
(% of total seeded monocytes)
Human lymphocyte migration 
(% of total seeded lymphocytes)
chemotactic molecule for PMN, and it was involved in PMN 
recruitment induced by ectopic FasL expression in tumor cells (27). 
Transient expression of the IL-1 receptor antagonist in L-ID cells 
had no effect at 24 hours but inhibited by almost 80% the in vivo 
PMN recruitment induced by L-ID cells at 72 hours compared with 
control Adpgal-transduced L-ID cells (Fig. 3D). In coincidence 
with the lack of involvement of FasL in vivo at 24 hours, incuba­
tion of L-ID cells with neutralizing anti-FasL antibody had no 
effect on hPMN migration in vitro (Fig 35). Overall, these data 
indicate that the persistence of PMN recruitment to the site of 
injection of SPARC-sup cells requires the involvement of FasL and 
IL-1 at a later stage.
In vivo coadministration of melanoma cells with knocked 
down SPARC expression with nonengineered melanoma cells 
promotes complete tumor rejection. Our initial in vivo studies 
suggested that SPARC knockdown in melanoma cells promoted 
not only the recruitment of PMN but also triggered their 
antitumor cytotoxic capacity. This effect was potent enough to 
induce rejection of a mix of tumor cells composed of L-ID cells 
coinjected with nonengineered human melanoma cells. Indeed, 
nude mice xenografted with ratios of 1:1, 1:0.67, and 1:0.25 
(control cells: L-ID cells) showed no tumor growth (Table 1). Even 
at 1:0.1 ratio, only 22% of mice (2 of 7) showed tumor growth for 
2 weeks, which then ceased growing and remained stable until 
the end of the experiment (Table 1). Rejection of L-ID + L-[3gal 
cell growth was accompanied by the massive recruitment of 
PMNs similar to what has been previously described in Fig. 15 
and F (Supplementary Fig. SIC and D). No viable tumor cells 
were observed after 5 days (data not shown). On the other hand, 
L-CMV + L-3gal site of injection showed a PMN infiltrated 
similarly to what has been described in Fig. 15 and C (data not 
shown). This bystander effect was not cell line specific because 
tumor growth was significantly reduced in mice xenografted 
with a 1:1 ratio of another human melanoma cell line IIB-MEL-J 
to L-ID cells (Table 1). Rejection of this cell combination was also 
associated with the massive recruitment of PMNs (Supplementary 
Fig. S2). From these studies, it can be concluded that knockdown 
of SPARC expression in malignant cells is sufficiently potent to 
stimulate the elimination of bystander nonmodified cells, even 
when L-ID cells accounted for only 10% of injected cells. 
Interestingly, SPARC produced by the bystander cells was unable 
to revert the effect.
Modulation of SPARC levels in human melanoma cells 
regulates the antitumor cytotoxic capacity of human poly­
morphonuclear leukocytes in vitro. Finally, we did in vitro 
studies to confirm that SPARC produced by melanoma cells 
modulates hPMN antitumor cytotoxic activity. First, we observed 
an increased capacity of hPMN to adhere to either of the SP-AS 
cell clones compared with control L-CMV cells (Supplementary 
Fig. S3/I). This binding was almost completely abrogated in the 
presence of anti-CD18 antibody and partially inhibited in the 
presence of anti-CD54 and anti-CD31 antibodies (data not 
shown). In addition, SP-AS CCM induced a strong PMN 
azurofilic granule exocytosis, indicating increased activation of 
hPMN compared with L-CMV cells (Supplementary Fig. 35). 
Mostly important, hPMNs exerted a potent cytotoxic activity 
against SP-AS cells, but not against control L-CMV or parental 
IIB-MEL-LES cells (Fig. 4A and data not shown). In line with 
this, transient knockdown of SPARC expression in A375N human 
melanoma cells following ex vivo transduction with AdSP-AS also 
triggered the antitumor cytotoxic capacity of hPMN, whereas
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Infiltrating PMN 
(total amount of PMN in 20 fields)
hPMN migration 
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Log-io(fluorescence)
24 hr 72 hr
Figure 3. Factors involved in PMN recruitment. A, effect of IL-8, GRO. FasL, and leukotriene neutralization on in vivo mPMN recruitment at 24 and 72 hours after 
melanoma cell injection. Columns, mean number of recruited PMN of four mice; bars, SE. *, P < 0.05; **, P < 0.001. Only clearly viable PMNs were counted.
B, inhibition of hPMN migration after treatment of melanoma cell-conditioned media obtained from L-CMV and L-1D cells with anti—IL-8, anti-GRO, and anti-FasL 
neutralizing antibodies and MK886. Columns, average migration as percentage of total PMN; bars, SE. The data for L-1D cells correspond to a representative 
experiment of three with similar results, done with PMN obtained from selected donors. The data for L-CMV cells correspond to a representative experiment done 
with samples from five donors. *, P < 0.05; **, P < 0.01, ANOVA for each antibody or inhibitor treatment compared with the untreated cell-conditioned media.
C, expression of Fas and FasL at the cell surface of melanoma cells. FACS analysis was done as described in Materials and Methods with specific antibodies 
(shaded histogram) or isotypic control antibodies (white histogram). D, transient expression of IL-1 receptor antagonist (IL-1RA) in L-1D cells inhibited mPMN 
recruitment in vivo. L-1D cells were transduced with an adenoviral dose of 5 x 10s TCID50/mL, 24 hours before injection in mice. Columns, mean number of recruited 
PMN of four mice; bars, SE. **, P < 0.001.
control cells transduced with Adjigal had no effect (Fig. 45). In 
close coincidence with the in vivo data showing rejection of 
bystander nonengineered melanoma cells, hPMNs were able to 
kill parental IIB-MEL-LES and control L-CMV cells when these 
cells were mixed with L-ID cells even at a ratio of 4:1 (Fig. 4C 
and data not shown). This bystander effect was only observed in 
the presence of L-ID cells, whereas L-ID-derived conditioned 
media or extracellular matrix had no effect (data not shown). 
This result indicates that hPMN must directly interact with L-ID 
cells to trigger their cytotoxic capacity against control cells.
To further confirm that the cytotoxic activity of hPMN is under 
SPARC control, we transiently reexpressed SPARC in L-ID cells 
using an AdSPARC vector. Treatment of L-ID cells with AdSPARC at 
5 x 108 TCID50/mL, which transduced on average 55% of L-ID cells, 
reverted hPMN-mediated L-ID lysis by almost 50% compared with 
Adpgal-transduced cells (Fig. 5/1). Lack of complete reversion was 
probably due to the stimulation of hPMN cytotoxicity by non­
transduced cells. In coincidence, addition of 125 and 500 nmoI/L 
native SPARC partially reverted hPMN cytotoxic capacity induced 
by L-ID cells (Fig. 55), demonstrating that SPARC produced 
by human melanoma cells modulates PMN antitumor cytotoxic 
activity.
Isolated hPMNs enter by default to an apoptotic program in vitro 
(28). Coincubation of hPMN with L-ID cells grown as a monolayer 
had no effect on PMN apoptosis as measured by annexin V staining 
(Fig. 5C). On the contrary, PMN apoptosis was reduced by almost 
20% in the presence of L-CMV cells (Fig. 5C). These results were 
confirmed by visual inspection of PMN nuclear morphology; 62.7 ± 
8.1% (mean ± SE of six experiments) of control hPMN seemed 
apoptotic compared with 50.4 ± 5.3% in the presence of L-ID cells 
(mean ± SE; P = 0.13, compared with the control, Wilcoxon rank 
test) and with 17.2 ± 5.0% in the presence of L-CMV cells (mean ± 
SE; P < 0.01, compared with the control). Moreover, incubation of 
hPMN with SPARC also induced 44 ± 7% and 46 ± 4% (mean ± SE 
of three experiments) decreases in the proportion of apoptotic 
hPMN compared with medium alone as determined by annexin V 
or propidium iodide staining, respectively (Fig. 5D and data not 
shown). These results indicate that SPARC inhibition of hPMN lytic 
capacity against melanoma cells might be linked with the 
inhibition of hPMN apoptosis.
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L-1D L-CMV
Table 1. In vivo rejection of different human melanoma 
cells coinjected with L-1D cells
1:0* 1:1 1:0.67 1:0.25 1:0.1 1:1
IIB-MEL-LES 13/14*-* 0/8 0/8 0/15*
L-CMV 13/13*
L-Pgal 10/10* 0/5 2/7
IIB-MEL-J 9/10 2/10 9/10
NOTE: Control cells (5 x 106) were coinjected with different amounts 
of L-1D cells in the left flank of nude mice, and tumor growth was 
monitored in all the experiments for 6 months.
*Ratio of coinjected cells (i.e., IIB-MEL-LES: L-1D).
t Number of mice that developed tumors per total number of mice, 
iCumulative data from two independent experiments.
express FasL induced a strong PMN-mediated inflammatory 
response (25). These conflicting results were partially explained 
by the presence of transforming growth factor 3 (TGF[3) at 
immune privileged sites, which seemed to block the proinflam- 
matory activity of FasL (37). Interestingly, SPARC has been shown 
to induce TGF|'> expression and to stimulate the TGF|'> signaling 
pathway (38, 39), suggesting a potential link between SPARC, 
TGF3, and FasL on the activation of PMN recruitment and 
inflammation. Despite some discrepancy (40), SPARC-null mice 
showed enhanced inflammatory responses compared with wild­
type littermates in three different murine models (41, 42), opening 
the intriguing possibility that SPARC might also regulate 
inflammatory processes in other scenarios as well.
SPARC expression and activation of polymorphonuclear 
leukocyte antitumor activity. The in vivo data indicate that 
persistent PMN recruitment is crucial for rejection of SPARC-sup
Discussion
Here, we report a cohesive set of data demonstrating that 
SPARC plays an essential role in the direct modulation of 
the antitumor PMN cytotoxic capacity. In addition, knockdown of 
SPARC expression by human melanoma cells promoted the in vivo 
recruitment of mPMN to the site of injection of tumor cells and 
the in vitro transmigration of hPMN toward melanoma cells.
SPARC expression and polymorphonuclear leukocyte re­
cruitment. We found a clear correlation between the increased 
in vivo recruitment of mPMN at 24 hours and the increased in vitro 
migration of hPMN following knockdown of SPARC expression. 
This effect seems to be mediated by chemotactic factors produced 
by the melanoma cells themselves, suggesting that SPARC might 
modulate a unique signaling pathway that converges into the 
regulation of leukotrienes, IL-8, and GRO. IL-8 and GRO 
transcription is stimulated by nuclear factor kB activity (29, 30) 
but, although the signaling pathways leading to leukotriene 
production had been explored (31), no link between nuclear factor 
kB and leukotriene production has been reported. Potential 
mediators of SPARC signaling are cell surface integrins. In that 
respect, integrin activation by fibronectin induced IL-8 and GRO 
expressions in melanoma cells and monocytes (32, 33). In addition, 
integrins modulate leukotriene production and secretion by 
neutrophils (34). Because SPARC regulates fibronectin levels in 
endothelial cells (35) and modulates integrin-mediated melanoma 
cell adhesion to different matrices,6 we hypothesize that SPARC 
might act on an integrin-dependent pathway to regulate IL-8, GRO, 
and leukotriene production.
6 M.J. Alvarez et al., manuscript in preparation.
FasL and IL-1 are required in the second stage of PMN 
recruitment that follows knockdown of SPARC expression, 
suggesting their link to SPARC within a unique signaling pathway. 
IL-1 production was not detected in melanoma cells, suggesting 
that it is produced by host cells, most probably by apoptotic 
PMNs. FasL expression by melanoma cells has been initially 
associated with tumor escape by virtue of its immune suppressive 
activity at privileged sites (36). However, cells engineered to
E / T Ratio
B
Ratio (L-1D : IIB-MEL-LES)
Figure 4. In vitro activation of PMN cytotoxic capacity against melanoma cells. 
A, in vitro dose-dependent cytolysis of L-1D and L-1E cells by hPMN.
■ , L-CMV; ▲, L-1E; •, L-1D. Points, mean; bars, SE. Representative of four 
experiments. *, P < 0.001. B, in vitro lysis of A375N cells by hPMN following 
transduction of A375N cells with AdSP-AS at 5 x 107TCID50/mL. PMN cytotoxic 
activity was assessed 24 hours after cell transduction. Columns, mean of six 
independent experiments; bars, SE. *, P < 0.001. C, in vitro cytolytic activity 
of hPMN against 51Cr-labeled IIB-MEL-LES cells cocultured with different 
amounts of L-1D cells. Points, mean; bars, SE. Representative of three 
experiments. *, P < 0.001. B to E, ratio of PMN to melanoma cells was 25:1.
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TCID50/ml; 5x107 5x108
Basal L-CMV L-1D
Figure 5. SPARC inhibits PMN cytotoxic activity against 
L-1D cells. A, SPARC reexpression in L-1D cells inhibits 
hPMN cytotoxicity against melanoma cells. Cytotoxic activity 
of hPMN was assessed 24 hours after adenovirus-mediated 
gene transfer. Columns, mean of four independent 
experiments (white columns, L-CMV cells; black columns, 
L-1D cells); bars, SE. *, P < 0.001. Inset, SPARC 
immunoblot of 1 pg of total protein produced by L-CMV and 
L-1D cells 48 hours after adenovirus-mediated gene transfer. 
Numbers indicate the relative absorbance of each band.
B, purified human SPARC inhibits hPMN-mediated 
cytotoxicity of L-1D cells in vitro. Columns, mean of four 
independent experiments; bars, SE. **, P < 0.0001.
C, control L-CMV but not SP-AS L-1 D cells inhibit the default 
apoptosis program of hPMN in vitro. Annexin V staining of 
hPMN preincubated 16 hours with L-CMV or L-1D cells. Only 
metabolically active cells, identified by propidium iodide 
exclusion, were analyzed by flow cytometry. Proportion of 
apoptotic cells in percentage. D, SPARC protein inhibits the 
default apoptosis program of hPMN in vitro. Apoptosis was 
evaluated by annexin V staining as depicted in C.
D
Basal SPARC 500 nM
cells. However, melanoma cells expressing SPARC did also promote 
the initial recruitment of PMNs that were unable to inhibit tumor 
growth. This, in turn, was followed by a decrease in PMN 
recruitment. Based on this evidence, we propose that SPARC levels 
are critical in directing PMN activation. Moreover, the lytic activity 
of PMNs obtained from all the donors was regulated by SPARC, 
indicating that SPARC is a key molecule in this process. If SPARC 
expression is suppressed, the intimate contact between PMNs and 
tumor cells promotes their antitumor cytotoxic activation. 
However, if high SPARC levels repress their activation, recruited 
PMN could favor tumor establishment. In agreement with this 
hypothesis, a dual PMN functionality is currently being suggested 
by the literature. PMN potentiates tumor progression of squamous 
epithelial carcinoma through degradation of extracellular matrix, 
activation of fibroblasts, and enhanced angiogenesis (43). More­
over, mouse melanoma cells require host PMN for rapid growth 
after injection in nude mice (44). On the other hand, PMNs do play 
an effector role in tumor rejection on activation with cytokines, 
chemokines, or FasL expression (14). The molecular basis for this 
dual role of PMN is still unclear as it is difficult to reconcile the 
dual role of IL-8 and GRO as chemotactic factors for PMN and 
autocrine growth factors for melanoma growth. Recently, it was 
shown that IL-8 production by melanoma cells stimulated the 
in vivo growth of a metastatic melanoma cell line in the presence 
of a strong but inactive PMN infiltrate (45). In the same study, 
IL-8 induced a PMN-mediated rejection of another nonmetastatic 
melanoma cell line, suggesting that a metastatic “status” dictates 
whether IL-8 will promote tumor progression or regression (45). 
Instead, we propose that PMN activation is not related to the 
metastatic status but to the presence or not of a PMN “trigger 
signal” in malignant cells. In the absence of this signal, PMN 
recruited by chemotactic signals will eventually promote tumor 
progression (21). Thus, tumor cell rejection by PMN is not merely 
dependent on their recruitment but there are further downstream 
signals necessary to activate them locally. We propose that SPARC 
might modulate a general mechanism that governs both PMN 
recruitment and activation. An intriguing possibility is that SPARC 
might affect PMN capacity to attack tumor cells by modulating 
their apoptotic default pathway. It can be hypothesized that the 
inhibition of PMN apoptosis in vivo might avoid recruitment of 
further waves of PMN and then favor tumor establishment.
The fact that exogenously added SPARC reverted the in vitro 
lytic capacity of PMN but was unable to revert the in vivo 
bystander effect even when SPARC-producing cells accounted for 
90% of total injected cells might indicate a role for additional yet 
unidentified proteins in vivo that might be involved in tumor 
rejection and are under SPARC regulation. Alternatively, endoge­
nous SPARC might induce an intracellular change that exogenous 
SPARC is unable to revert. SPARC is widely accepted as a secreted 
protein that seems to exert its effect from outside the cell. 
However, very recent evidence indicates that SPARC might be 
intracellularly incorporated by certain cell types and translocated 
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to the nuclei (46). Moreover, we observed SPARC expression in 
nuclei of human melanoma samples through immunohistochem­
ical studies using a SPARC specific antibody.7 Finally, both 
alternatives might coexist in vivo.
7 M.J. Alvarez, data not shown.
Role of SPARC produced by malignant cells in tumor 
progression. SPARC expression was associated with the neoplastic 
progression of different types of human cancer. Interestingly, 
SPARC is expressed by malignant cells, fibroblasts, and tumor 
endothelium in melanomas and gliomas (47, 48), whereas it is 
mainly expressed by tumor fibroblasts and tumor endothelium in 
most adenocarcinomas (9, 10). An intriguing question is whether 
SPARC produced by the malignant cells has a different role 
compared with SPARC produced by tumor stroma cells. In this 
regard, SPARC expression by the malignant cells stimulated the 
invasive capacity of melanoma and glioma cells (4, 6, 49), whereas 
exogenously added SPARC obtained from different sources 
promoted migration of prostate and breast cancer cells toward a 
bone extract, indicating its possible role in the tropism of 
adenocarcinoma cells for metastatic sites (5). Recent attempts to 
elucidate the role of host-derived SPARC using SPARC null mice led 
to controversial results (42, 50). Whereas Brekken et al. (50) showed 
enhanced tumor growth in SPARC null mice, Sangaletti et al. (42) 
showed impaired tumor growth in SPARC null mice. Whereas these 
differences might depend on the tumor model, both studies 
suggested a link between tumor formation and host-dependent 
extracellular matrix assembly, which in our studies was impossible 
to assess due to the prompt recruitment of PMN and rejection of 
malignant cells. The present study, in which the modulated variable 
(SPARC production by the tumor cell) is indeed the one that 
changes during some tumorigenic processes (47, 48), validates and 
strengthens the role of SPARC as a direct inhibitor of the antitumor 
cytotoxic capacity of PMN and suggests its potential use as a target 
for cancer therapy.
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